PRISMAP outcomes

PRISMAP produces a wide range of results that we make available to you:

As a research project, PRISMAP publishes results in peer-reviewed scientific journals and other non peer-reviewed venue, and also makes detailed reports – called 'deliverables' – available, if they can be made publicly accessible.

We also make available recordings of the webinars and training sessions organised by PRISMAP, along with the material created to describe the project and how it works.

You can also find links to our funded projects page and to our educational resources, which are part of our multi-faceted outcomes.

Publications

Publishable summary

Download the latest project summary detailing the status of PRISMAP as prepared for the EU funding body and the public.

Public deliverables

Deliverables are reports to the EU funding body on the results achieved for one or more project tasks.
1.
PRISMAP Deliverable D10.6 - Report on precursor synthesis and related infrared spectroscopy measurements.
(2023). doi: 10.5281/ZENODO.10091918
2.
PRISMAP Public Report D9.2 Compliant and efficient transportation.
(Zenodo, 2023). https://zenodo.org/doi/10.5281/zenodo.10069352.
3.
Deliverable D6.5 MOOC on the basis of In the Heart of Medical Radioactivity.
(2023). doi: 10.5281/ZENODO.10057649
4.
Nuclear data for day-1 radionuclides.
(2023). doi: 10.5281/ZENODO.8247129
5.
PRISMAP Deliverable D8.1 - Proceedings book workshop 1.
(2023). doi: 10.5281/ZENODO.7913190
6.
Deliverable 5.1 - Questionnaire on industrial and clinical key players and needs.
(2022). doi: 10.5281/ZENODO.7154340
7.
Prismap D9.1-First public report from the PRISMAP work package 9 (WP9, transport and logistics).
(Zenodo, 2022). https://zenodo.org/record/6606494.
8.
Standards for clinical translation.
(2022). doi: 10.5281/ZENODO.6599181
9.
DFT calculations for Ca and Ti containing molecules.
(2022). doi: 10.5281/ZENODO.6607408

Scientific publications

Publications in peer-reviewed journals, conference proceedings, book chapters and books.
1.
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Theranostics 14, 1720–1743 (2024). doi: 10.7150/thno.92775. Archive: PMC
2.
Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide.
Frontiers in Chemistry 11, 1288588 (2023). doi: 10.3389/fchem.2023.1288588. Archive: BORIS
3.
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?.
EJNMMI Radiopharmacy and Chemistry 8, 27 (2023). doi: 10.1186/s41181-023-00211-5. Archive: PMC
4.
Resonant laser ionization and mass separation of 225Ac.
Scientific Reports 13, 1347 (2023). doi: 10.1038/s41598-023-28299-4. Archive: CDS
5.
Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 542, 137–143 (2023). doi: 10.1016/j.nimb.2023.05.008. Archive: CDS
6.
DFT calculations of Ti-based molecules clustering with Ar for laser-based enrichment of stable isotopes.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 141–143 (2023). doi: 10.1016/j.nimb.2023.05.040. Archive: CDS
7.
Determination of the Terbium-152 half-life from mass-separated samples from CERN-ISOLDE and assessment of the radionuclide purity.
Applied Radiation and Isotopes 202, 111044 (2023). doi: 10.1016/j.apradiso.2023.111044. Archive: PMC
8.
First on-line application of the high-resolution spectroscopy laser ion source PI-LIST at ISOLDE.
Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 541, 8–12 (2023). doi: 10.1016/j.nimb.2023.04.057
9.
Can we reach suitable 161Tb purity for medical applications using the 160Gd(d,n) reaction?.
Applied Radiation and Isotopes 200, 110927 (2023). doi: 10.1016/j.apradiso.2023.110927. Archive: HAL
10.
Improved procedures for production and purification of 135La from enriched [135Ba]BaCO3 on a 16.5 MeV cyclotron.
Applied Radiation and Isotopes 192, 110612 (2023). doi: 10.1016/j.apradiso.2022.110612. Archive: DTU Orbit
11.
Study of terbium production from enriched Gd targets via the reaction 155Gd(d,2n)155Tb.
Applied Radiation and Isotopes 201, 110996 (2023). doi: 10.1016/j.apradiso.2023.110996. Archive: HAL
12.
Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State.
Diagnostics 12, 3176 (2022). doi: 10.3390/diagnostics12123176. Archive: PMC
13.
Thermal and Structural Characterization of a Titanium Carbide/Carbon Composite for Nuclear Applications.
Materials 15, 8358 (2022). doi: 10.3390/ma15238358. Archive: PMC
14.
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [153Sm]Sm-DOTA-TATE.
Pharmaceutics 14, 2566 (2022). doi: 10.3390/pharmaceutics14122566. Archive: SCK CEN Publications
15.
Excitation functions of deuteron induced nuclear reactions on dysprosium targets for the production of the theranostic relevant isotopes of terbium.
The European Physical Journal Plus 137, 1180 (2022). doi: 10.1140/epjp/s13360-022-03378-z. Archive: HAL
16.
67Cu Production Capabilities: A Mini Review.
Molecules 27, 1501 (2022). doi: 10.3390/molecules27051501. Archive: PMC
17.
Half-life determination of 155Tb from mass-separated samples produced at CERN-MEDICIS.
Applied Radiation and Isotopes 190, 110480 (2022). doi: 10.1016/j.apradiso.2022.110480. Archive: cds
18.
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS.
Frontiers in Medicine 8, 712374 (2021). doi: 10.3389/fmed.2021.712374. Archive: PMC
19.
Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?.
Frontiers in Medicine 8, 678452 (2021). doi: 10.3389/fmed.2021.678452. Archive: PMC
20.
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy.
Journal of Nuclear Medicine 62, 1495–1503 (2021). doi: 10.2967/jnumed.120.261016. Archive: PMC
 

Funded projects

PRISMAP selects projects for funding and serves as provider of radionuclides and medical application services for these projects.

The selected projects are presented on our access platform with title, leader, keywords, a publishable abstract and, if available, a summary of the results and a list of related publications.

Publications by funded projects

1.
Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161 Tb and 177 Lu: A Comparative Study.
Journal of Nuclear Medicine jnumed.123.266233 (2023). doi: 10.2967/jnumed.123.266233

Webinars and trainings

PRISMAP provides training for the highly multidisciplinary and fragmented research community.

A common understanding and common terms will enable users, service providers and regulators to speak the same language.

Recordings of previous webinars promoted by PRISMAP look at production of radionuclides, regulatory aspects, theranostics.

For a full list of events, webinars and training sessions organised by the project, please visit our events page.

Project presentation

With this series of short videos and the flyer, we would like to introduce the project, its goals and its way of working to a wide audience.

Educational content

PRISMAP offers education and training resources aimed at high school or early university students, but anyone is welcome to use them.

The available information can be downloaded from the dedicated educational resources section of our website and freely used in educational settings.